IMMUNOHISTOCHEMISTRY D2-40 PODOPLANIN Test
Test Name: IMMUNOHISTOCHEMISTRY D2-40 PODOPLANIN Test
Components: Price: 510.0 AED
Sample Condition: Submit tumor tissue in 10% Formal-saline OR Formalin fixed paraffin embedded block. Ship at room temperature. Provide a copy of the Histopathology report, Site of biopsy and Clinical history.
Report Delivery: Sample Daily by 6 pm; Report Block: 5 days Tissue Biopsy: 5 days Tissue large complex: 7 days
Method: Immunohistochemistry
Test type: Cancer
Doctor: Oncologist
Test Department: HISTOLOGY
Pre Test Information: Provide a copy of the Histopathology report, Site of biopsy and Clinical history.
Test Details
The D2-40 (podoplanin) immunohistochemistry test is a diagnostic tool used to detect the expression of podoplanin in tissue samples. Podoplanin is a transmembrane glycoprotein that is expressed in various tissues, including lymphatic endothelial cells, kidney podocytes, and certain tumors. The D2-40 antibody is used in this test to specifically target podoplanin.
The tissue sample is typically obtained through a biopsy or surgical procedure. The sample is then fixed, embedded in paraffin, and sectioned onto glass slides. The immunohistochemistry process involves the following steps:
- Deparaffinization: The paraffin-embedded tissue sections are deparaffinized using xylene or other clearing agents.
- Antigen retrieval: Heat-induced antigen retrieval is performed to unmask the target epitopes and improve antibody binding. This is typically done by heating the slides in a buffer solution.
- Blocking: Non-specific binding sites on the tissue sections are blocked using a protein blocking solution, such as bovine serum albumin (BSA) or normal serum.
- Primary antibody incubation: The D2-40 antibody is applied to the tissue sections and allowed to bind to the podoplanin antigen. The sections are then incubated at an appropriate temperature for a specific duration.
- Secondary antibody incubation: A secondary antibody, conjugated with a detection system such as horseradish peroxidase (HRP) or alkaline phosphatase (AP), is applied to the tissue sections. This secondary antibody binds to the primary antibody and allows for visualization of the antigen.
- Visualization: The detection system is visualized using a chromogenic substrate that produces a colored precipitate at the site of antibody binding. This allows for the identification of podoplanin-positive cells or tissues.
- Counterstaining: In some cases, a counterstain, such as hematoxylin, is applied to the tissue sections to provide contrast and enhance visualization of the cells or tissue structures.
The results of the D2-40 immunohistochemistry test are typically interpreted by a pathologist. Podoplanin expression can vary depending on the tissue type and disease state. The test can help in the diagnosis and characterization of various conditions, including lymphatic disorders, tumor metastasis, and certain types of cancers. It is important to note that immunohistochemistry results should be interpreted in conjunction with other clinical and pathological findings to reach a definitive diagnosis.
Test Name | IMMUNOHISTOCHEMISTRY D2-40 PODOPLANIN Test |
---|---|
Components | |
Price | 510.0 AED |
Sample Condition | Submit tumor tissue in 10% Formal-saline OR Formalin fixed paraffin embedded block. Ship at room temperature. Provide a copy of the Histopathology report, Site of biopsy and Clinical history. |
Report Delivery | Sample Daily by 6 pm; Report Block: 5 days Tissue Biopsy: 5 days Tissue large complex : 7 days |
Method | Immunohistochemistry |
Test type | Cancer |
Doctor | Oncologist |
Test Department: | HISTOLOGY |
Pre Test Information | Provide a copy of the Histopathology report, Site of biopsy and Clinical history. |
Test Details |
The D2-40 (podoplanin) immunohistochemistry test is a diagnostic tool used to detect the expression of podoplanin in tissue samples. Podoplanin is a transmembrane glycoprotein that is expressed in various tissues, including lymphatic endothelial cells, kidney podocytes, and certain tumors. The D2-40 antibody is used in this test to specifically target podoplanin. The tissue sample is typically obtained through a biopsy or surgical procedure. The sample is then fixed, embedded in paraffin, and sectioned onto glass slides. The immunohistochemistry process involves the following steps: 1. Deparaffinization: The paraffin-embedded tissue sections are deparaffinized using xylene or other clearing agents. 2. Antigen retrieval: Heat-induced antigen retrieval is performed to unmask the target epitopes and improve antibody binding. This is typically done by heating the slides in a buffer solution. 3. Blocking: Non-specific binding sites on the tissue sections are blocked using a protein blocking solution, such as bovine serum albumin (BSA) or normal serum. 4. Primary antibody incubation: The D2-40 antibody is applied to the tissue sections and allowed to bind to the podoplanin antigen. The sections are then incubated at an appropriate temperature for a specific duration. 5. Secondary antibody incubation: A secondary antibody, conjugated with a detection system such as horseradish peroxidase (HRP) or alkaline phosphatase (AP), is applied to the tissue sections. This secondary antibody binds to the primary antibody and allows for visualization of the antigen. 6. Visualization: The detection system is visualized using a chromogenic substrate that produces a colored precipitate at the site of antibody binding. This allows for the identification of podoplanin-positive cells or tissues. 7. Counterstaining: In some cases, a counterstain, such as hematoxylin, is applied to the tissue sections to provide contrast and enhance visualization of the cells or tissue structures. The results of the D2-40 immunohistochemistry test are typically interpreted by a pathologist. Podoplanin expression can vary depending on the tissue type and disease state. The test can help in the diagnosis and characterization of various conditions, including lymphatic disorders, tumor metastasis, and certain types of cancers. It is important to note that immunohistochemistry results should be interpreted in conjunction with other clinical and pathological findings to reach a definitive diagnosis. |